tbuckley/cabot-search huggingface dataset:
Modeling synovial sarcoma metastasis in the mouse: PI3′-lipid signaling and inflammation
Authors: Jared J. Barrott, Lisa A. Kafchinski, Huifeng Jin, Jared W. Potter, Sarmishta D. Kannan, Robert Kennedy, Tim Mosbruger, Wei-Lien Wang, Jen-Wei Tsai, Dejka M. Araujo, Ting Liu, Mario R. Capecchi, Alexander J. Lazar, Kevin B. Jones
Journal: The Journal of Experimental Medicine (2016)

Solid tumor metastasis is a complex biology, impinged upon by a variety of dysregulated signaling pathways. PI3′-lipid signaling has been associated with metastasis and inflammation in many cancers, but the relationship between tumor cell–intrinsic PI3′-lipid signaling and inflammatory cell recruitment has remained enigmatic. Elevated PI3′-lipid signaling associates with progression of synovial sarcoma, a deadly soft tissue malignancy initiated by a t(X;18) chromosomal translocation that generates an SS18-SSX fusion oncoprotein. Here, we show in genetically engineered mouse models of locally induced expression of SS18-SSX1 or SS18-SSX2 that Pten silencing dramatically accelerated and enhanced sarcomagenesis without compromising synovial sarcoma characteristics. PTEN deficiency increased tumor angiogenesis, promoted inflammatory gene expression, and enabled highly penetrant spontaneous pulmonary metastasis. PTEN-deficient sarcomas revealed infiltrating myeloid-derived hematopoietic cells, particularly macrophages and neutrophils, recruited via PI3′-lipid–induced CSF1 expression in tumor cells. Moreover, in a large panel of human synovial sarcomas, enhanced PI3′-lipid signaling also correlated with increased inflammatory cell recruitment and CSF1R signal transduction in both macrophages and endothelial cells. Thus, both in the mouse model and in human synovial sarcomas, PI3′-lipid signaling drives CSF1 expression and associates with increased infiltration of the monocyte/macrophage lineage as well as neutrophils.
Direct and Natural Killer Cell-Mediated Anti-Tumor Effects of Low-Dose Bortezomib in Hepatocellular Carcinoma.
Authors: Matthias Krusch, Sorin Armeanu, Katrin M. Baltz, Ulrich M. Lauer, Alexander Steinle, Lothar Kanz, Michael Bitzer, Helmut R. Salih
Journal: Blood (2007)
Survival Impact of Patients (Pts) with Chronic Myeloid Leukemia (CML) Due to Failure from the Use of One or More Tyrosine Kinase Inhibitors (TKI)
Authors: Mary Akosile, Sherry Pierce, Mark Brandt, Srdan Verstovsek, Gautam Borthakur, Hagop Kantarjian, Farhad Ravandi, William Wierda, Guillermo Garcia-Manero, Naval Daver, Tapan Kadia, Jan A. Burger, Naveen Pemmaraju, Elias Jabbour, Jorge E. Cortes
Journal: Blood (2015)
Early childhood development: a new challenge for the SDG era
Authors: Aluisio J D Barros, Fernanda Ewerling
Journal: The Lancet Global Health (2016)

After the success of the Millennium Development Goals and the reduction in more than 50% of child mortality in children younger than 5 years (Countdown to 2015 report),1 the survive and thrive motto was given prominence by the Sustainable Development Goals (SDGs).2 For all children to thrive, we need equitable early development worldwide, entailing that every girl and boy should have the same opportunities to fully develop their potential, which is only achievable if they have good nutrition, good health, and a rich and stimulating home environment.
Dentistry: should it be in the NHS at all?
Authors: John Appleby
Journal: BMJ (2016)

When the NHS opened for business in 1948 two of its biggest product lines quickly became the supply of spectacles and dentures. According to the British Dental Association, in the first nine months of the NHS, dentists provided over 33 million artificial teeth, 4.5 million extractions, and 4.5 million fillings. Dental surgeries were overwhelmed by the demand for treatment.1 Since then dentistry has moved on from drilling, filling, and extraction—but so too has the public’s dental demands. Are we approaching a point where it will become increasingly hard to justify tax funding for dentistry? Is the perfect smile a medical necessity worthy of public subsidy?

There is no doubt that the nation’s gnashers have improved tremendously over time. In 1968 a staggering 37% of the adult population of England and Wales had no teeth.2 A decade later, in England, this proportion had fallen to 28%, and by 2009 it was just 6%.3 Over …
PWE-075 Changing Patterns of Management and Outcomes for Early Oesophageal Adenocarcinomas in England and Wales
Authors: G Chadwick, D Cromwell
Journal: Gut (2016)

<h3>Introduction</h3> Currently only 1 in 20 oesophageal adenocarcinomas are diagnosed at early stage.<sup>1</sup> Where patients are diagnosed at an early stage, studies have suggested that up to 90% of patients managed with curative surgical intent survive 5 years.<sup>2</sup> In this study we investigated the changing patterns of management for oesophageal adenocarcinomas in England and Wales, and associated patient outcomes. <h3>Methods</h3> This study uses data collected for the National Oesophago Gastric Cancer Audit (NOGCA), and compares patients diagnosed in the year following 1<sup>st</sup> April 2008 (Group 1), with those diagnosed five years later in 2013 (Group 2). The study was limited to patients diagnosed with early stage (T0/1, N0, M0) oesophageal adenocarcinoma. Outcomes considered included proportion of patients managed with curative intent, curative treatment modality and patient outcomes at 1 year. <h3>Results</h3> A similar number of patients were diagnosed with early stage cancer over both time frames, Group 1 (n = 202) and Group 2 (n = 193). The proportion of patients managed with curative intent increased over the five years from 77.4% to 83.4% (chi-square test, p = 0.13). However the proportion of patients aged ≥75 years managed with curative intent increased significantly between 2008 and 2013, from 48% to 67% (p = 0.02). These increases are likely to reflect changes in curative treatment modalities. Over the last five years, there has been a significant increase in the proportion of patients managed with less invasive curative treatment modalities, with the proportion being managed endoscopically increasing from 18% to 34%, while there was a corresponding decrease in the proportion managed surgically from 76% to 61% (p = 0.007). Patients diagnosed with early cancer in 2013 who were managed with curative intent were significantly more likely to survive 1 year than those who had been diagnosed in 2008 (98% vs 93%, p = 0.05). <h3>Conclusion</h3> Outcomes for patients diagnosed with early oesophageal adenocarcinomas have improved over the last five years. Over the same period, the proportion of patients managed with less invasive endoscopic treatment modalities has increased significantly. However, it should be noted that a sizeable minority of patients are still being managed with palliative intent. The NOGCA will continue to monitor the management of this group of patients in future. <h3>References</h3> 1 Chadwick G, <i>et al</i>. Management and survival of patients with early stage oesophageal adenocarcinomas in England: a population-based cohort study. <i>British Journal of Surgery</i>. 2 Wani S, <i>et al</i>. Comparison of endoscopic therapies and surgical resection in patients with early esophageal cancer: a population-based study. <i>Gastrointest Endosc</i>. 2014;<b>79</b>(2):224–32.e1. <h3>Disclosure of Interest</h3> None Declared
Bortezomib May Be Safely Combined with Y-90 Ibritumomab Tiuxetan In Patients with Relapsed/Refractory Follicular or Transformed Non-Hodgkin Lymphoma: A Phase I Trial of Combined Induction Therapy and Bortezomib Consolidation
Authors: Rupali Roy, Andrew M Evens, David P. Patton, Annette Larsen, Alfred Rademaker, Jeffrey Cilley, Stewart Spies, Daina Variakojis, Leo I Gordon, Jane N. Winter
Journal: Blood (2010)
SAT0132 Presence of Psychological, Sexual and Sleep Disorders in Patients with Rheumatoid Arthritis
Authors: P. Santos-Moreno, L. Villarreal, G. Ballesteros, J. Bello, E. Castillo, R. Giraldo, D. Gomez, A. Aza, A. Lopez, A. Cardozo, N. Palacio, C. Castro, D. Buitrago-Garcia
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> The rheumatoid arthritis (RA), as known, causes inability in various performance areas mostly in the musculoskeletal, but few is known about psychological, sleep and sexual problems. <h3>Objectives</h3> The aim of this study is to describe the socio-demographic profile of patients with RA in specialized RA clinic in Colombia, where we identified disorders in areas besides the physical or musculoskletal, like psychological, sexual and sleep. <h3>Methods</h3> A descriptive study was performed in a specialized clinic dedicated to care patients with RA. 1298 RA patients were included in the study, which were seen by the area of psychology; information was collected through semi-structured interviews and non-probability sampling, also using classificatory criteria of pathologies described in CIE 10 diagnostic manual, applying descriptive epidemiology for continuous variables, measure of central tendency and dispersion for qualitative and categorical variables through percentages and averages. <h3>Results</h3> Total sample of patients was 1298, 1048 (80%) were women and 250 (19%) were men. Patients had a DAS28 2.6 in average ± 1.1; mean age was 55.1 ± 8.8 years; 58% of patients were medium socio-economical level and the 34% were low socio-economical level; 59% were married, 18% were divorced, 14% is single and 6% were widowed. Related with the occupation, 25% were retired because age and 10% had handicap retirement pay; 24% were dedicated to housekeeping and 35% were working. Related to education 6% were illiterate, 44% had elementary school, 33% high school, 8% had a technical degree and only 7% had college level. According to CIE-10 739 patients (57%) had psychological disorders, 279 patients (21%) had sexual and 373 (28%) had sleep disorders. <h3>Conclusions</h3> According to these findings there is a high prevalence of patients with low-medium socio-economical levels in RA which shows a possible correlation of a socio-demographic unfavorable situation with presence of disease. Also there are high rates of psychological, sexual and sleep comorbidities, which implies that measures must be implemented in order to improve these areas of performance in patients with RA. <h3>Disclosure of Interest</h3> None declared
OC-011 EMR VS ESD for Barrett’s Neoplasia: Time to Shift the Paradigm?: Abstract OC-011 Table 1
Authors: F Chedgy, S Subramaniam, K Kandiah, S Thayalasekaran, P Bhandari
Journal: Gut (2016)

<h3>Introduction</h3> The risks of ESD in the oesophagus are perceived to be high and consequences potentially disastrous. For this reason, EMR is the most common technique to resect early Barrett’s cancer. However, the drawback of EMR is piecemeal resection with difficulties interpreting resection margins of cancers. The aim of this study was to evaluate feasibility, safety, and outcomes of ESD in the endoscopic treatment of Barrett’s neoplasia and to compare these with EMR. <h3>Methods</h3> All data was collected prospectively on a predesigned electronic database between 2006 and 2015. The database was interrogated by independent researchers blinded to the endoscopic procedures. Bleeding was defined as significant if patients required transfusion, endoscopic therapy or hospitalisation. Strictures were defined as significant if they were symptomatic or requiring dilatation. SPSS was used for statistical analysis of data <h3>Results</h3> 81 oesophageal ESDs were performed in 70 patients and 180 EMRs were performed in 112 patients during the study period. Table 1 demonstrates patient and lesion characteristics and outcomes following resection including deep R0 resection margin for cancer and histological outcomes. Lesion morphology and histology was significantly more advanced in the ESD group as compared to EMR. The endoscopic cure rate in the EMR group was 81% with 19% of patients upstaged requiring radical treatment. In the ESD group the endoscopic cure rate was 87% with 13% of patients upstaged requiring radical treatment. <h3>Conclusion</h3> This is the biggest reported comparison of EMR vs ESD for Barrett’s neoplasia. Proportionately more Is and IIC lesions were resected by ESD than by EMR which is reflected by significantly more cancers identified in the ESD group. Our data shows the safety and efficacy for ESD resection of Barrett’s cancers but EMR still remains a standard therapeutic option for non-cancerous Barrett’s neoplasia. This calls for a prospective RCT comparing ESD vs EMR for Barrett’s cancer. <h3>Disclosure of Interest</h3> None Declared
Neuropeptide Y Y1 receptor-mediated biodegradable photoluminescent nanobubbles as ultrasound contrast agents for targeted breast cancer imaging
Authors: Juan Li, Yuchen Tian, Dingying Shan, An Gong, Leyong Zeng, Wenzhi Ren, Lingchao Xiang, Ethan Gerhard, Jinshun Zhao, Jian Yang, Aiguo Wu
Journal: Biomaterials (2016)
Pbx-1 Is a Direct Target of Evi-1 in Hematopoietic Stem/Progenitors and Leukemic Cells.
Authors: Munetake Shimabe, Susumu Goyama, Motoshi Ichikawa, Yoichi Imai, Tsuyoshi Takahashi, Akira Hangaishi, Mineo Kurokawa
Journal: Blood (2008)
SAT0494 Bacteriologic Profile of Septic Arthritis: A Retrospective Study of 59 Cases
Authors: A. Bachali, H. Sahli Ep Hedi, R. Tekaya, I. Mahmoud, R. Khalfallah, O. Saidane, L. Abdelmoula
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Septic arthritis (SA) is an infection of synovial tissue that can affect one or more joints in patients of any age. It is considered as a medical and therapeutic emergency. Diagnosis is based on the presence of a microorganism in joint aspiration or in withdrawal of a possible gateway or a secondary location. <h3>Objectives</h3> To describe the bacteriologic profile of SA among adult subjects in a rheumatologic department. <h3>Methods</h3> This is a descriptive retrospective study including records of cases of SA collected in a rheumatology department, over a period of 17 years [1998–2014]. The epidemio-clinical features and evolution were noted. Bacteriologic exams were collected and analyzed. <h3>Results</h3> Fifty nine records of 59 patients with SA were selected. The mean age was 54.6 ± 19 years [range 15 to 95]. There were 28 men and 31 women with a sex ratio M/F =0.9. Fifty 50 cases (84.7%) had a single joint involvement, 6 cases (10.2%) had oligoarticular arthritis and 3 cases had polyarticular arthritis (5.1%). The joint aspiration was performed in 53 patients (89.8%). The appearance of the liquid was clear in 6 cases (11.5%), hematic in 5 cases (9.6%), purulent in 18 cases (34, 6%) and trouble in 23 cases (44.2%). White blood cells varied between 4000 and 100,000/mm<sup>3</sup> with an average of 27.520 elements. Direct bacteriologic exam was positive in 16 cases (30.8%). Twenty seven subjects (46%) had a positive culture. The study of the synovial fluid identified staphylococcus as the most frequently isolated microorganism (5 cases), followed by Streptococcus (3 cases), Koch bacillus (2 cases) and E.Coli (2 cases). One patient had septic arthritis due to Neisseria gonorrhoeae. <h3>Conclusions</h3> The bacteriologic profile is this series is not different than known in literature but showed that less than a half of patients had an identified microorganism as defined the SA. <h3>Disclosure of Interest</h3> None declared
Leukemic Presentation Is Predictive Indicator for Relapse for Patients with Follicular Lymphoma Treated with Rituximab Containing Initial Therapy.
Authors: Makoto Kodaira, Kengo Takeuchi, Eriko Nara, Kenji Nakano, Kyoko Ueda, Shuhei Yamada, Yuko Mishima, Masahiro Yokoyama, Yasuhito Terui, Kiyohiko Hatake
Journal: Blood (2009)
Association of Polymorphisms of Cytosine Arabinoside- Metabolizing Enzyme Gene with Therapy Efficacy for Acute Myeloid Leukemia
Authors: Peipei Xu, Baoan Chen, Ran Liu, Jifeng Feng, Lu Cheng, Guohua Xia, Yufeng Li, Jun Qian, Jiahua Ding, Han Zhu, Zuhong Lu
Journal: Blood (2012)
P139 The burden of copd across the european union: development of the european copd atlas
Authors: JFM van Boven, J Gaughan, JB Soriano, J Correia de Sousa, N Baxter, M Román-Rodríguez, J Vilaró, S Williams, S Fitch, K Kishore, H Chaudhury
Journal: Thorax (2016)

<h3>Background</h3> Estimating current and future impact of chronic obstructive pulmonary disease (COPD) within the European Union (EU) is essential for targeted and well-informed policy-making, however, current global and regional estimates are contradictory, and comparable standardised data is lacking. Without it the burden felt by individuals and healthcare systems cannot be fully quantified and a collective and coordinated response cannot be achieved to protect economies and communities from further harm. <h3>Aim</h3> Our purpose was to Collect data to enable a comparative assessment of the COPD burden across EU 28 member states and highlight variation. Show the impact of COPD in the workplace, on healthcare utilisation and on quality of life of the EU population. Use the data to underpin a simulation model to demonstrate future impact on societies, health inequalities and healthcare utilisation depending on which interventions are selected. <h3>Methods</h3> A systematic literature review was performed to identify regional and national data on COPD prevalence, risk factors (e.g. smoking, air pollution), impact and costs across the EU. Workshops with stakeholders from a range of European countries were convened to test the face validity of the data, and to develop policy-level questions from which a simulation model could be developed. <h3>Results</h3> Prevalence estimates of COPD varied considerably (1.26% to 13.87%), partly because of different definitions. As smoking rates are less affected by definition differences, these were used in a model that predicts COPD incidence, prevalence and mortality. Correction factors were applied to account for non-smoking related causes and under diagnosis of smoking. Smoking prevalence rates were used to estimate data for equivalent countries for the countries where smoking data were not available. The simulation model is currently in development and first results are expected in Autumn 2016. <h3>Conclusion</h3> The European COPD Coalition (ECC) will use the results to facilitate dialogue with EU decision makers (European Commission Council and Parliament) on health policy, outlining the problem and providing evidence to support the call for political actions on COPD. It will also be of significant interest to healthcare professionals, patients, and respiratory organisations with a passion to improve COPD care
Abstract 17636: Low Rates of Oral Anticoagulation Use Among Patients Hospitalized With Atrial Fibrillation and at High Risk for Stroke
Authors: Sean D Pokorney, Elaine M Hylek, John Fastenau, Jennifer Davidson, CV Damaraju, Bimal R Shah, Roberta A James, John A House, Christopher B Granger
Journal: Circulation (2016)

Introduction: Despite an increased risk of stroke with atrial fibrillation (AF), outpatient prescription data suggest approximately half of AF patients with guideline indications for oral anticoagu...
Targeted Replacement of the Murine Thrombomodulin Gene with Human Thrombomodulin Coding Sequence Results in Decreased Protein C Activation and Enhanced Thrombotic Response to Photochemical Injury.
Authors: Thomas J. Raife, Rochelle A. Erger, Katina M. Wilson, Jose A. Fernandez, Jennifer Alternburg, Hyung-Suk Kim, John H. Griffin, Nobuyo Maeda, Steven R. Lentz
Journal: Blood (2004)
Oral Small Molecule Inhibitor of VLA-4 Overcomes Adhesion Mediated Chemotherapy Resistance of Acute Myeloid Leukemia (AML) Blasts in Vitro, without Impairment of Normal Blood Cell Recovery When Combined with Chemotherapy in Vivo
Authors: Pamela s. Becker, Frederick R. Appelbaum, Sylvia Chien, Xin Zhao, Halvard Bonig, Ryuta Mukasa, Thalia Papayannopoulou
Journal: Blood (2008)
Fludarabine Melphalan and Alemtuzumab (Campath) Conditioning for Pts with High Risk Myeloid Malignancies. High Cure Rate for Pts with Low Leukemia Burden.
Authors: Koen W. van Besien, Andrew Artz, Sonali Smith, Elizabeth Rich, Lucy Godley, Demetria Jones, Paula Del Cerro, Diane Switzer, Brendan Casey, Olatoyosi Odenike, Michael Thirman, Chris Daugherty, Todd M. Zimmerman, Richard Larson, Wendy Stock
Journal: Blood (2004)
Splenectomy Favours Development of Extramedullary Hematopoiesis in the GATA-1low Model of Myelofibrosis.
Authors: A. M. Vannucchi, F. Martelli, A. Pancrazzi, P. Guglielmelli, F. Almerigogna, M. Valeri, E. Alfani, G. Migliaccio, A.R. Migliaccio
Journal: Blood (2005)
Reduction of Prothrombin in Mice Carrying a Conditional Knockout Allele Attenuates the Development of Paralysis Associated with Experimental Encephalitis.
Authors: Eric S. Mullins, Keith W. Kombrinck, Matthew J. Flick, Maureen A. Shaw, William Sun, Sandra J. Degen, Katerina Akassoglou, Jay L. Degen
Journal: Blood (2007)
Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma
Authors: Jeffrey S. Weber, F. Stephen Hodi, Jedd D. Wolchok, Suzanne L. Topalian, Dirk Schadendorf, James Larkin, Mario Sznol, Georgina V. Long, Hewei Li, Ian M. Waxman, Joel Jiang, Caroline Robert
Journal: Journal of Clinical Oncology (2017)

Purpose We conducted a retrospective analysis to assess the safety profile of nivolumab monotherapy in patients with advanced melanoma and describe the management of adverse events (AEs) using established safety guidelines. Patients and Methods Safety data were pooled from four studies, including two phase III trials, with patients who received nivolumab 3 mg/kg once every 2 weeks. We evaluated rate of treatment-related AEs, time to onset and resolution of select AEs (those with potential immunologic etiology), and impact of select AEs and suppressive immune-modulating agents (IMs) on antitumor efficacy. Results Among 576 patients, 71% (95% CI, 67% to 75%) experienced any-grade treatment-related AEs (most commonly fatigue [25%], pruritus [17%], diarrhea [13%], and rash [13%]), and 10% (95% CI, 8% to 13%) experienced grade 3 to 4 treatment-related AEs. No drug-related deaths were reported. Select AEs (occurring in 49% of patients) were most frequently skin related, GI, endocrine, and hepatic; grade 3 to 4 select AEs occurred in 4% of patients. Median time to onset of select AEs ranged from 5 weeks for skin to 15 weeks for renal AEs. Approximately 24% of patients received systemic IMs to manage select AEs, which in most cases resolved. Adjusting for number of doses, objective response rate (ORR) was significantly higher in patients who experienced treatment-related select AEs of any grade compared with those who did not. ORRs were similar in patients who did and patients who did not receive systemic IMs. Conclusion Treatment-related AEs with nivolumab monotherapy were primarily low grade, and most resolved with established safety guidelines. Use of IMs did not affect ORR, although treatment-related select AEs of any grade were associated with higher ORR, but no progression-free survival benefit.
Symptomatic Waldenstrom’s Macroglobulinemia (WM) in Young Patients: Disease Characteristics and Outcome.
Authors: Efstathios Kastritis, Evangelos Eleftherakis-Papaiakovou, Magdalini Migkou, Dimitra Gika, Evangelos Terpos, Konstantinos Zervas, Marie Christine Kyrtsonis, Nicolaos Anagnostopoulos, Sossana Delimpassi, Argiris Symeonidis, Meletios Athanasios Dimopoulos
Journal: Blood (2007)
Regulation and Targeting of Eg5 in Blast Crisis CML: Overcoming Imatinib Resistance.
Authors: Bing Z. Carter, Duncan Mak, Yue-Xi Shi, Wendy D. Schober, Rui-Yu Wang, Teresa McQueen, Marina Konopleva, Erich Koller, Nicholas M. Dean, Michael Andreeff
Journal: Blood (2005)